I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress
Stockholm, August 25, 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. has announced that two abstracts have been accepted for oral and poster presentation at the upcoming European Association of Nuclear Medicine (EANM) 2023 Congress, which will be held in Vienna, September 9-13, 2023. The EANM oral presentation represents the fifth oral presentation at prestigious medical conferences globally in 2023 including TCT, EBMT, SNMMI, and EHA. The presentation reflects that I131-apamistamab increases access to allogeneic hematopoietic stem cell transplant for patients with relapsed or